Polyketides (PKSs) are secondary metabolites produced by microorganisms with important pharmaceutical applications [1] . However, the production yield of these bioactive metabolites is often low in native hosts, largely because their biosynthetic gene clusters (BGCs) are mostly silent, or their starting substrates limited. To improve the production yield of PKSs, multiple strategies have been developed, including metabolic engineering the native hosts or heterologously overexpressing their BGCs in a different host [2, 3] .
production of jadomycin B and oxytetracycline, respectively. Moreover, they were able to increase the titer of avermectin B 1a (an anti-pesticide drug) by 50% to 9.31 g l −1 in a 180-m 3 industrial-scale fermentation. This is the highest titer ever reported in the literature. In summary, this study demonstrated the potential of regulating cellular TAG pool to boost multiple PKSs in various Streptomyces isolates.
A previous study [6] enabled the high-titer production of a simple polyketide triacetic acid lactone in a nonconventional yeast Y. lipolytica via overexpressing the peroxisome biogenesis factor gene PEX10 responsible for converting acyl-CoA to acetyl-CoA. In this work, Palmer et al. engineered Y. lipolytica to biosynthesize more complex polyketides like naringenin, resveratrol, and bisdemethoxycurcumin. The biosynthetic machinery of these 4-coumaroyl-CoA-derived PKSs utilize both 4-coumaric acid and acetyl-CoA as starting substrates. To boost their production titer, they heterologously expressed pathways for 4coumaric acid production (via 4-coumaroyl-CoA) and employed a βoxidation related strategy to increase acetyl-CoA accumulation. This combination allows the strain to produce several phenylpropanoid-derived polyketides including naringenin, resveratrol, and bisdemethoxycurcumin et al. by feeding Y. lipolytica with 4-coumaric acid, and achieved the highest titer of naringenin ever reported. In conclusion, these results revealed that the metabolically engineered yeast Y. lipolytica is an optimal host for the high-level production of complex, phenylpropanoid-derived PKSs.
Both studies utilize metabolic engineering strategies targeting the degradation of TAGs (lipids) towards acetyl-CoA to improve PKS production titer in the host. The PKS substrates, like acetyl-CoA and malonyl-CoA, could derive from various carbon sources and it will be very interesting to systematically explore the genes and pathways that could shunt the carbon flux toward acetyl-CoA and malonyl-CoA, and presumably increase PKS titer in a native host. Moving forward, it will be interesting to test if this strategy will boost the production titer of other characterized PKSs in different bacterial or even fungal hosts. It will also be more exciting to explore if this strategy will elicit the production of some cryptic or silent PKSs, because in general, the total number of PKS biosynthetic gene clusters still outnumbered the number of PKSs that have been reported in the literature.
